Shares in Varian Medical (NYSE:VAR) have fallen slightly today after the medical device maker posted fiscal year 2019 second quarter earnings that topped sales expectations but missed on earnings per share consensus on Wall Street.
The Palo Alto, Calif.-based company posted profits of $88.4 million, or 96¢ per share, on sales of $779.4 million for the three months ended March 29, for bottom-line growth of 20.8% while sales grew 6.8% compared with the same period during the previous year.
Adjusted to exclude one-time items, earnings per share were $1.05, just behind the $1.15 consensus on Wall Street where analysts expected to see sales of $776.3 million, which the company topped.
“In the second quarter, we maintained strong momentum. Each of our geographies delivered exceptional orders growth, including strong double-digit performance in APAC and the seventh consecutive quarter of double-digit growth in EMEA. Based on the company’s results year-to-date and our outlook for the rest of the year, we are raising our fiscal year revenue guidance to 6 to 9% while increasing investments in growth priorities such as groundbreaking preclinical research with our FlashForward Consortium,” CEO Dow Wilson said in a press release.
Varian raised its guidance for its fiscal year 2019, expecting to post sales of between $3.09 billion and $3.18 billion, up from previous guidance of between $3.06 billion and $3.15 billion.
The company reiterated its non-GAAP earnings per share guidance, expecting to post between $4.60 and $4.75 for the full year.
Shares in Varian are down approximately 1.2% today, at $131.64 as of 10:28 a.m. EDT.
Earlier this month, Varian said that it won an approximately $7.1 million delivery order against a five-year basic ordering agreement to supply the U.S. Department of Defense with two linear accelerator systems.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.